Latest news & insights
Professor Alan Boyd explains the science behind gene therapy in Open Access Government article
An article authored by President and CEO, Professor Alan Boyd, was recently featured in Open Access Government.
Experts at Boyds talk funding for cell and gene therapy development
Dr Nick Meyers, Vice President of Product Development, and Dr Neil Fish, Vice President of Business Development, recently discussed the availability of funding for cell and gene therapy product development with Cell and Gene Therapy Insights.
Spring Budget: R&D tax relief rate announcement
In the Spring Budget, the Chancellor has announced an enhanced R&D tax relief rate for ‘R&D intensive SMEs.’ Professor Alan Boyd, CEO and president of Boyds, responds to the news.
Further growth for regulatory affairs team at Boyds with appointment of Harriet Edwards
We are pleased to announce the appointment of experienced regulatory professional, Harriet Edwards, in response to a sustained rise in demand for specialist regulatory services
Rare Disease Day: Gene therapy trends and innovation for rare diseases
To mark Rare Disease Day 2023, Professor Alan Boyd, President and CEO of Boyds, spoke to Cell and Gene Therapy Insights to share his views on gene therapy trends and innovation in the rare and ultra-rare disease spaces.
Eamonn McGowran explains developments in regulation for medical devices in Med-Tech Innovation article
An article published in Med-Tech Innovation and authored by Eamonn McGowran, explains the developments in regulation for Medical devices.
Dr Karen Mullen interviewed for pharmaphorum article
Dr Karen Mullen, Chief Medical Officer at Boyds, recently sat down with pharmaphorum, a leading online destination for healthcare and pharmaceutical industry news.
Boyds regulatory affairs article published by Drug Discovery World
An article authored by Dr Julie Warner, Vice President of Regulatory Affairs, has been featured by Drug Discovery World – the multi-platform global voice for the drug discovery community.
